Peptidergic nootropic therapy in cerebral palsy associated with epilepsy
Observational study · 2017
- What was studied
- 84 children with cerebral palsy and epilepsy
- Main finding
- Adjunctive Cortexin with antiseizure medicines was associated with varied motor and seizure outcomes; one seizure aggravation was reported.
Both seizure and motor improvement · 31/84 (36.9%) · Seizure frequency more than halved
Reported findings and study design
84 children aged 1–11 with cerebral palsy plus epilepsy: 55 boys, 29 girls. Add-on Cortexin 5–10 mg IM depending on age/weight, alongside antiepileptic medication.
Population or model 84 children with cerebral palsy and epilepsy
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Both seizure and motor improvement | 31/84 (36.9%) | Seizure frequency more than halved |
| Motor improvement without major seizure change | 15/84 (17.8%) | |
| More than halved seizures without motor improvement | 14/84 (16.7%) | |
| No response | 23/84 (27.4%) | |
| Seizure aggravation | 1/84 (1.2%) | A girl with West syndrome |
Uncontrolled add-on cohort; cannot establish comparative benefit or safety.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- The report describes no randomized untreated comparator. Seizure safety remains uncertain.
- Pediatric clinical findings do not establish enhancement or safety in healthy adults.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Kholin AA, Zavadenko NN, Il Ina ES, Kolpakchi LM, Fedonyuk ID, Bembeeva RC, Esipova ES. Peptidergic nootropic therapy in cerebral palsy associated with epilepsy Zh Nevrol Psikhiatr Im S S Korsakova 117(9):37-42. PMID 29053119
Study source ↗ · DOI 10.17116/jnevro20171179137-42 · Bibliography entry · Link to this summary